CORT

Corcept does not benefit from meaningful network effects in the classic sense. The value of Korlym or Recorlev does not rise because more patients use them, and one physician’s prescribing choice does not materially improve outcomes for another. There is some indirect reinforcement from accumulated clinical experience, publication history, and disease awareness among endocrinologists, but that is better described as brand building and evidence generation than a network effect. The market is too medically specialized and too small for a platform dynamic to emerge. As a result, the company gains little self-reinforcing value from scale on the demand side, and competitors would not face a network disadvantage if they launched credible alternatives.

Switching costs are meaningful but not prohibitive. Patients with Cushing’s syndrome often require careful dose titration, ongoing monitoring of glucose, blood pressure, potassium, and side effects, and close coordination with endocrinologists. Once a patient is stabilized, physicians may be reluctant to change therapy because symptom relapse or adverse-event management can be disruptive. That said, the barrier is clinical friction rather than true lock-in. If a payer prefers another product, if tolerability worsens, or if a competing therapy offers a better risk-benefit profile, switching is feasible. Corcept’s products therefore enjoy moderate inertia, especially in chronic use, but the company cannot rely on deep operational switching costs to keep prescribers or patients indefinitely.

Corcept’s most important advantage is its portfolio of intangible assets: FDA approvals, orphan-drug status history, patents, and specialized know-how in cortisol modulation. Korlym was the first approved oral therapy for endogenous Cushing’s syndrome, which created a durable clinical lead and a brand position in a difficult-to-treat niche. Recorlev extends that asset base with a newer molecule and additional protection. However, the underlying mechanism is scientifically understandable, the field is not closed to competitors, and the company cannot depend forever on exclusivity windows. The protection is strong enough to support premium pricing and first-call habits among specialists, but it must be continuously refreshed through new data, new molecules, and new indications.

Corcept has some cost discipline from its narrow focus and relatively concentrated commercial model, but it does not possess a durable structural cost advantage over rivals. The company historically outsourced much of its manufacturing and development work, which limits vertical integration benefits. A focused sales force and a rare-disease target can reduce wasted commercial spend, but that is not the same as a lower-cost production or distribution system. High pricing is supporting economics here, not low unit cost. A larger pharmaceutical company could plausibly match or exceed Corcept’s capabilities with sufficient commitment. The result is a modest, execution-driven cost position rather than a structural advantage that would be hard for competitors to narrow.

Corcept operates in a small therapeutic niche where only a limited number of companies can profitably invest, which creates some efficient-scale protection. The Cushing’s syndrome patient pool is small, the physician base is concentrated, and the regulatory and educational burden of serving the market is meaningful. Those factors discourage casual entry and make it difficult for many firms to justify the commercial effort. Still, this is not a natural monopoly or a true duopoly in the classic sense. A rival with a compelling clinical profile could enter and take share, and the market is not so large that one participant must control it to earn attractive returns. Efficient scale helps, but only moderately.